Nemes Laszlo/iStock via Getty Images Tempest Therapeutics ( NASDAQ: TPST ) shares dropped Thursday after the company updated data from an ongoing trial designed to test its PPAR⍺ antagonist, amezalpat (TPST-1120), as a first-line combination therapy for those with hepatocellular carcinoma. Citing a Feb. 14 data cut, the Brisbane, California-based biotech said amezalpat led to a six-month survival advantage with cancer drugs atezolizumab and bevacizumab, marketed as Tecentriq and Avastin by Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ).
The global Phase 1b/2 study tested amezalpat in combination with atezolizumab and bevacizumab against the standard of care, atezolizumab, and bevacizumab in previously untreated patients with unresectable or metastatic HCC. Patients who received the amezalpat combo lived a median of 21 months (overall survival) compared to 15 months for those who received the standard of care. The experimental therapy demonstrated a safety profile consistent with Phase 1 data.
Tempest ( TPST ) added. The latest readout didn’t indicate data related to the study’s main efficacy goal, the confirmed objective response rate ((cORR)), which stood at 30% for the amezalpat arm and 13.3% for the control arm in a previous analysis in April.
More on Tempest Therapeutics Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch Tempest Therapeutics reports Q1 results Seeking Alpha’s Quant Rating on Tempest Therapeutics Historical earnings data for Tempest Therap.
